Homepage / Technology / A scientific breakthrough offers hope for an AIDS vaccine
Google and Facebook are watching our every move online. It's time to make them stop Daymond John tells shy airline passenger: You should have talked to me on the plane South Korea says it has no plans to shut down cryptocurrency trading AMD shares surge as Wall Street analysts say the chipmaker is ‘executing on all fronts’ James Altucher, the face of bitcoin, says he’s happy about Facebook’s cryptocurrency ad ban Pending home sales eke out 0.5 percent gain in December as supply shrinks to record low Uber is testing bike sharing in San Francisco The real source of the internet's problems might be the advertising business Game publisher EA's sales forecast tops estimates, sending shares higher GE will likely be dropped from the Dow, Deutsche Bank predicts Samsung surpasses Intel as world's biggest chipmaker for the first time Apple could be the best of the bunch in this tech earnings avalanche The 9-year stock rally still has 'years left,' says one of Wall Street's most bullish strategists Apple: We would never degrade the iPhone experience to get users to buy new phones Bitcoin headed for biggest monthly drop since January 2015 with nearly $60 billion of value wiped off ADP boosts forecast as new tax law spurs demand China 'will open even wider to the UK,' says Prime Minister Li Keqiang Big market swings are something you’re going to have to get used to, says Wells Fargo The dollar keeps weakening. Is that good news for the world? Apple downgraded by BMO, expects iPhone maker to slash revenue forecast this week SoftBank buys majority stake in Japanese messaging giant Line’s mobile division Rising interest rates cause a 2.6% pullback in weekly mortgage applications Trump's State of the Union address 'less hard' than first feared in Asia Trump vows to protect US intellectual property, without naming China Blockchain technology to boost Microsoft earnings, trader says Fujifilm to take over Xerox and combine it into the joint venture Fuji Xerox Samsung is making chips designed to mine cryptocurrencies like bitcoin There’s a risk of market turbulence, but it’s unlikely to hit until 2019, says Santander chairman We'll see up to a 15 percent correction in 2018, Swiss bank CEO says Japan's biggest messaging app Line is planning to launch a cryptocurrency exchange Quicksilver surfwear CEO missing at sea off the coast of France Venezuela says will pre-sell 'petro' cryptocurrency on Feb. 20 Nintendo ups its Switch sales expectations to 15 million units after profits rise 261% European markets seen mixed amid earnings and economic data The UK wants free trade with China. Beijing has its own goals Santander fourth-quarter net profit down 4 percent on US impairments The man who almost became ambassador to South Korea just warned about US plans for North Korea China's Leshi Internet flags $1.8 billion loss for 2017, citing conglomerate cash crunch South Korea says it uncovered about $600 million in cryptocurrency crimes Asia became less democratic in 2017 Al Gore's investment firm backs start-up created by Facebook co-founder Theresa May says she wants a free trade deal with China Chinese manufacturing weaker than expected in January Webpass is leaving Boston in latest sign of Google Fiber’s shrinking ambitions Samsung posts record fourth-quarter profit Asian shares look set for more declines as Wall Street sells off for a second day Don't count insurers out yet after Amazon-Berkshire-JP Morgan move Amazon's health care move could be a big win for consumer health start-ups Red Hat buys CoreOS, a start-up that sold tech developed by Google Here’s what Amazon told employees today about its landmark deal to deliver better health care Top official resigns after false missile alert in Hawaii Crazy odds: These online traders bet on the chaos of Washington and the Trump administration AMD falls despite beating Q4 estimates Facebook ban on bitcoin ads latest in very bad day for cryptocurrencies Indian man dies after being sucked into an MRI machine while carrying an oxygen cylinder Advice for Jeff Bezos, Warren Buffett and Jamie Dimon from a failed effort to control health costs Toys R Us poor holiday sales cast doubts on its future and could force renegotiation of loan terms The Apple sell-off is a buying opportunity into earnings, says trader Google partnership on mobile cloud services drives up MobileIron shares Facebook is banning all ads promoting cryptocurrencies — including bitcoin and ICOs Amazon's moves in health care over the last year are finally starting to make sense Buffett is getting a second chance to partner with Bezos after missing on Amazon as an investment How Pencils of Promise got a $1 million donation from an anonymous bitcoin multi-millionaire Amazon's home devices could be a key to cheaper health care, tech investor Roger McNamee says Two ex-Google engineers built an entirely different kind of self-driving car Cryptocurrencies join the global financial market sell-off as bitcoin drops 7% A travel agent is trying to charge fees for sunbeds Most of the tax cut windfall will boost buybacks and dividends, not workers' pockets, survey predicts The professor who wrote the book on making addictive technology is having second thoughts Trump's immigration policies are 'economic poison' that will cost taxpayers billions Airbnb trolls President Trump ahead of the State of the Union The iPhone X's $1,000 price tag scared everyone away Drop, a rewards app start-up, snags Airbnb's former head of engineering SEC halts one of the largest 'ICOs' ever as it wades deeper into the murky world of cryptocurrency offerings Passing on sanctions, Trump goes even softer on Russia than expected Buy insurers on dip as new initiative from Amazon, Berkshire and JP Morgan is ‘more bark than bite’: Analyst High schools stock up on Narcan to combat teen opioid crisis in US Apple will finally replace the fax machine in health care Apple is reportedly delaying new iOS features until next year because of quality problems Bond expert predicts a ‘wall of buying’ in Treasurys will protect the stock market Home prices surge to new high, up 6.2% in November Noted tech investor says the sector is not the best place to invest right now Sterling predicted to hit pre-Brexit vote level before the end of 2018 Stocks making the biggest moves premarket: AMZN, BRKB, JPM, AAPL, BX, TSLA & more Bitcoin boom to give AMD earnings a boost, says MKM Partners Apple shares fall again on another report of fading iPhone X demand Trump advisor Cohn: President to focus on $1.5 trillion infrastructure plan in State of the Union Why don't foreign investors take fright more often? The dollar is doing something it hasn’t done since 1987 UnitedHealth, CVS plunge on Bezos, Buffett and Dimon plan to improve U.S. health care Amazon, Berkshire and JPMorgan Chase to team in landmark new health care company Can earnings afford to slow down? 'Enemies of the USA': Russia slams America's list of oligarchs with ties to Putin The app that exposed the location of military bases with a heat map is reviewing its features For his next act, former Amex CEO Ken Chenault turns his focus on Silicon Valley Child experts: Just say ‘no’ to Facebook’s kids app Ryanair agrees to recognize British pilots union for first time Arab states are 'determined' to stick with reforms despite deepening 'frustration', IMF says The US 'oligarch list' is strikingly similar to Forbes’ richest Russians ranking Indian ride-hailing firm Ola expands to Australia to take on Uber

Technology

A scientific breakthrough offers hope for an AIDS vaccine

Scientists are inching toward developing a vaccine for AIDS, an immunodeficiency disease caused by the HIV virus that currently affects 36.7 million people worldwide, according to the World Health Organization.

In a paper published in the journal Science in September, scientists from the National Institutes of Health and Paris-based pharmaceutical company Sanofi described a “three-pronged” antibody, engineered in a lab, that binds to three critical sites on the HIV virus. By attacking the virus from three sides, the “trispecific” antibody creates a roadblock that even HIV — known for its constant mutating — should struggle to circumvent.

“This is very impressive and really very exciting for people who are looking for ways to prevent HIV acquisition,” said Rowena Johnston, director of research at amfAR, a foundation that raises money for the study of AIDS.

Though therapies for HIV/AIDS now allow people to more effectively manage the disease, it still claims 1 million lives around the world every year and represents about $3.5 billion in annual U.S. health-care costs. The rate of new infections in the U.S. has fallen in recent years, to 37,600 in 2014 (the most recent year for which stats are available). But in Africa — where two-thirds of all new infections occur — there were 960,000 new AIDS/HIV cases in 2016.

Further alarming health advocates is the Trump administration’s decision to slash its global HIV/AIDS spending by 24 percent, leaving nonprofits like the Bill & Melinda Gates Foundation scrambling to make up the shortfall. “There’s no way to balance a cut in a rich country’s generosity,” said Mr. Gates in September.

The promise of an AIDS vaccine has tempted, but eluded, scientists for decades. It’s been 37 years since Margaret Heckler, Secretary of Health and Human Services under President Ronald Reagan, infamously told reporters at the press conference announcing the discovery of AIDS that a vaccine would be ready for testing within two years. Twenty-one years after that, the New England Journal of Medicine — following the collapse of yet another promising phase-3 study — referred to the flagging search for an AIDS vaccine as “a Sisyphean onslaught of disappointments.”

HIV is spread through the sharing of specific bodily fluids — blood, semen, breast milk and vaginal or rectal fluids — which typically occur during intercourse or the sharing of intravenous needles. Once inside the body, HIV attacks a certain kind of immune-system cell known as CD4. By destroying these cells, the virus makes it harder for your body to fight off disease, increasing the risk of major illness from even minor infections.

But in recent years, scientists have discovered a kind of antibody in people living longer with the virus, which has reinvigorated the pursuit. Known as broadly neutralizing antibodies, these Y-shaped proteins — which occur in about 20 percent of infected people living with HIV for two or more years — helps defend against multiple strains of HIV and are thought to play a role in helping people fend off the infection. Multiple studies have since tested ways in which broadly neutralizing antibodies could help stave off HIV infection or slow its growth in those already infected.

More from Modern Medicine:
Growing old with HIV after decades of drug success
A party drug could become next blockbuster antidepression treatment
New cure under way for the 80 million people in US dealing with hair loss

Of course, the antibodies have their limitations. “Each individual antibody only binds to one very specific component of the HIV envelope, or the outer covering,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, who helped oversee the new study. But HIV is constantly mutating, so no single antibody can hold off the virus for long. Eventually, the virus will happen upon a mutation that allows it to get around the protection provided by the single antibody.

What the NIH and Sanofi scientists did was combine three broadly neutralizing antibodies into a single compound. Johnston, who was not involved in the research, compared the approach with antiretroviral therapy, which has become the standard in HIV treatment by slowing the virus’ growth through a strategic combination of drugs. “If you’re only taking one type of drug, then your HIV would escape from that,” she said. “It’s possible two would work, but three really seals the deal.”

The redundancy of three different antibodies makes escape-by-mutation practically impossible. “HIV would have to come up with such an elaborate set of mutations to escape from all three of these antibodies simultaneously that it’s almost certainly not going to happen,” she said.

Combining three antibodies into a single compound — a remarkable feat of engineering, noted Johnston — not only provides greater protection against the virus but is optimized to move swiftly through the arduous FDA-approval process.

“It’s very complicated to get approval to do a trial in which you’re trying to combine more than one thing,” said Johnston. “If you’re trying to do drug A and drug B, the FDA would prefer you start out looking at just drug A and just drug B before they give you permission to put A and B together.”

The trispecific antibody circumvents that process — an ancillary benefit that Fauci referred to as a “bonus.” “We weren’t thinking about the FDA when we did this,” he said.

If it proves safe and effective in humans, the drug could be used both as a vaccine and a treatment for people already living with the disease. A phase 1 trial is now slated to begin in late 2018. If all goes well, it could potentially be on the market within the next three years.

Still, Fauci was careful not to overstate the significance of the current findings.

“This is a solid incremental increase in our capability of dealing with and preventing HIV infection,” he said. “It’s significant, but it isn’t completely transforming.”

That could change, of course. But only time will tell. “It ain’t a breakthrough till it works,” Fauci said.

By Douglas Quenqua, special to CNBC.com

Source: Tech CNBC
A scientific breakthrough offers hope for an AIDS vaccine

Comments are closed.